NZ721534A - Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine - Google Patents
Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amineInfo
- Publication number
- NZ721534A NZ721534A NZ721534A NZ72153415A NZ721534A NZ 721534 A NZ721534 A NZ 721534A NZ 721534 A NZ721534 A NZ 721534A NZ 72153415 A NZ72153415 A NZ 72153415A NZ 721534 A NZ721534 A NZ 721534A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- preparation
- aminooxetan
- benzothiazepin
- quinazolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ721534A true NZ721534A (en) | 2018-02-23 |
Family
ID=52358790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ721534A NZ721534A (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (https=) |
| EP (2) | EP3248969B1 (https=) |
| JP (1) | JP6397501B2 (https=) |
| KR (1) | KR101841866B1 (https=) |
| CN (2) | CN109879837B (https=) |
| AR (2) | AR099134A1 (https=) |
| AU (1) | AU2015208244B2 (https=) |
| BR (1) | BR112016016978B1 (https=) |
| CA (1) | CA2934225C (https=) |
| ES (2) | ES2789798T3 (https=) |
| HR (2) | HRP20200715T1 (https=) |
| IL (1) | IL245882B (https=) |
| MX (1) | MX368110B (https=) |
| MY (1) | MY176210A (https=) |
| NZ (1) | NZ721534A (https=) |
| PL (2) | PL3097098T3 (https=) |
| RU (1) | RU2664643C2 (https=) |
| SG (1) | SG11201605916QA (https=) |
| SI (2) | SI3097098T1 (https=) |
| WO (1) | WO2015110446A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3322704B1 (en) | 2015-07-16 | 2019-11-27 | H. Hoffnabb-La Roche Ag | Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections |
| DK3324977T3 (da) | 2015-07-22 | 2022-10-17 | Enanta Pharm Inc | Benzodiazepinderivater som rsv-inhibitorer |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| BR112020006334A2 (pt) | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112021018335A2 (pt) | 2019-03-18 | 2021-11-23 | Enanta Pharm Inc | Derivados de benzodiazepina como inibidores de rsv |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AU2020357452B2 (en) | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
| WO2021083290A1 (en) * | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| WO2022182861A1 (en) | 2021-02-26 | 2022-09-01 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2025011580A1 (zh) * | 2023-07-10 | 2025-01-16 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| MXPA05008108A (es) * | 2003-02-21 | 2005-09-21 | Pharmacia & Upjohn Co Llc | Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos. |
| MXPA05011523A (es) * | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| JP2014530225A (ja) | 2011-10-11 | 2014-11-17 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス疾患の処置および予防のための化合物 |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
| EP2997028A1 (en) * | 2013-05-14 | 2016-03-23 | F.Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en not_active Ceased
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ721534A (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| PH12020551089A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MY195364A (en) | Amide Compounds for the Treatment Of Hiv | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| IN2014DN09173A (https=) | ||
| MY197698A (en) | Oxysterols and methods of use thereof | |
| MX340190B (es) | Compuestos para tratar infecciones por virus sincitial respiratorio. | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| MX2016001855A (es) | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. | |
| MX376029B (es) | Compuestos de isoindol. | |
| MX2014003701A (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
| TW201129572A (en) | Compounds for treating respiratory syncytial virus infections | |
| WO2015160907A3 (en) | Potent and selective inhibitors of hepatitis c virus | |
| WO2017034242A3 (ko) | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 | |
| IN2011CH03893A (https=) | ||
| EA201270786A1 (ru) | α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| EA033921B9 (ru) | Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа | |
| MX2016009250A (es) | Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio. | |
| HK1205509A1 (zh) | 二氢喹唑啉衍生物的钠化和钙化盐及它们用作抗病毒媒介的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2020 BY THOMSON REUTERS Effective date: 20181220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2021 BY THOMSON REUTERS Effective date: 20191217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2022 BY THOMSON REUTERS Effective date: 20201215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2023 BY THOMSON REUTERS Effective date: 20211207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2024 BY THOMSON REUTERS Effective date: 20221206 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2026 BY ANAQUA SERVICES Effective date: 20241219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2027 BY ANAQUA SERVICES Effective date: 20251217 |